🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In case you missed it– Genelux was in USA Today! Read the full article here: loom.ly/PfYvsqE #OvarianCancer #Stage4NeedsMore $GNLX

Genelux is a proud sponsor of the National Ovarian Cancer Coalition's "Ask The Experts" series. Join the Facebook Live session on December 12, 2024 at 6pm ET and listen to Dr. Barbara Buttin (City of Hope Chicago) and Dr. Natalie Godbee (City of Hope Atlanta) answer your

On December 16, Research Analyst Emily Bodnar will moderate a HCW@Home session with Genelux featuring Thomas Zindrick, President & Chief Executive Officer. They’ll discuss OLVI-Vec and its ongoing cancer trials. To join, please register at ct.to/n900Z9K $GNLX

Platinum resensitization strategies in the treatment of ovarian cancer could potentially unlock treatment options that were previously deemed ineffective but come with potential benefits and risks. #PRROC #ovariancancer Genelux

Transparency and integrity are non-negotiable in clinical trials. Every study is conducted with the highest standards of scientific rigor and ethics.   Learn more about the principles guiding clinical research, including the ongoing OnPrime Trial, and how they ensure reliable

Help us welcome Matt Pulisic to the Genelux team! Read the full press release, loom.ly/kY3wI5k #OvarianCancer #CancerResearch #Stage4NeedsMore #Biotech

Stay informed, stay empowered, and stay hopeful as we continue to explore new frontiers in ovarian cancer treatment through trials like OnPrime/GOG-3076. loom.ly/Vg1vBGs

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer! ✅ Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All

Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer. For more on this news, visit loom.ly/cShW9PQ #OvarianCancer #CancerResearch #Stage4NeedsMore #Biotech

Olvi-Vec monotherapy Phase 1b trial showed clinical benefit in 73% of patients w/ no dose-limiting toxicity & no maximum tolerated dose. The Phase 2 combination study showed promising clinical benefits & reversal of clinical platinum resistance. $GNLX #Stage4NeedsMore

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates! Want to read the full release? Visit loom.ly/Hi9Y034 #OvarianCancer #CancerResearch #Stage4NeedsMore #Biotech

Today, on World Ovarian Cancer Day, we honor the fighters, remember the lives lost, and stand with everyone affected. 💚 Early detection saves lives—let’s break the silence, raise awareness, and support ongoing research. #WorldOvarianCancerDay #KnowOvarianCancer

🦠 Historical data of chemotherapy in 4th line shows a median overall survival of only 9.8 months on a median fifth line of treatment, while Olvi-Vec Phase 2 patients achieved a mOS of 15.7 mos. #Stage4NeedsMore #DrugDevelopment #Biotech #Stage4NeedsMore #DrugDevelopment

Did you miss our fireside chat at the Citizens Life Sciences Conference? Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, discussed clinical-stage programs and upcoming milestones. ▶️ Watch the replay here: loom.ly/Xa8J8G4

Preliminary data from Genelux’s Phase 1b trial in platinum-relapsed/refractory small cell lung cancer (SCLC) shows early promise for Olvi-Vec immunochemotherapy. In the initial dose escalation cohorts, 71% of patients (5/7) achieved disease control, with tumor reductions in all

Happy 4th of July! - The Genelux Team! #Immunotherapy #Biotech #CancerResearch #ClinicalTrials

We are delighted to welcome Eric Groen to the Genelux team! Read the full press release, loom.ly/xZcy3is #Immunotherapy #Biotech #CancerResearch #ClinicalTrials